- Home
- ALTS vs ELEV Comparison
ALTS vs ELEV Comparison
Compare ALTS & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- ELEV
- Stock Information
- Founded
- ALTS 1976
- ELEV 2019
- Country
- ALTS United States
- ELEV United States
- Employees
- ALTS N/A
- ELEV N/A
- Industry
- ALTS
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- ELEV Health Care
- Exchange
- ALTS NYSE
- ELEV Nasdaq
- Market Cap
- ALTS 35.9M
- ELEV 37.6M
- IPO Year
- ALTS N/A
- ELEV 2021
- Fundamental
- Price
- ALTS $3.84
- ELEV $0.58
- Analyst Decision
- ALTS
- ELEV Strong Buy
- Analyst Count
- ALTS 0
- ELEV 5
- Target Price
- ALTS N/A
- ELEV $7.20
- AVG Volume (30 Days)
- ALTS 209.2K
- ELEV 860.8K
- Earning Date
- ALTS 12-27-2024
- ELEV 11-06-2024
- Dividend Yield
- ALTS N/A
- ELEV N/A
- EPS Growth
- ALTS N/A
- ELEV N/A
- EPS
- ALTS N/A
- ELEV N/A
- Revenue
- ALTS $7,110,000.00
- ELEV N/A
- Revenue This Year
- ALTS N/A
- ELEV N/A
- Revenue Next Year
- ALTS N/A
- ELEV N/A
- P/E Ratio
- ALTS N/A
- ELEV N/A
- Revenue Growth
- ALTS N/A
- ELEV N/A
- 52 Week Low
- ALTS $0.50
- ELEV $0.44
- 52 Week High
- ALTS $5.26
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- ALTS 68.94
- ELEV 43.94
- Support Level
- ALTS $3.33
- ELEV $0.60
- Resistance Level
- ALTS $4.00
- ELEV $0.70
- Average True Range (ATR)
- ALTS 0.35
- ELEV 0.08
- MACD
- ALTS 0.05
- ELEV -0.01
- Stochastic Oscillator
- ALTS 90.12
- ELEV 7.67
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.